Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 12950

1.

Increasing Accessibility to Long-Acting Reversible Contraception in a Public Health Setting.

DeBoer TH, Hensley JG.

Nurs Womens Health. 2018 Aug;22(4):302-309. doi: 10.1016/j.nwh.2018.06.004. Epub 2018 Jul 4.

PMID:
30077236
2.

Long-acting Reversible Contraception-Highly Efficacious, Safe, and Underutilized.

Wu JP, Moniz MH, Ursu AN.

JAMA. 2018 Jul 24;320(4):397-398. doi: 10.1001/jama.2018.8877. Review. No abstract available.

PMID:
29984374
3.

Comparative efficacy of oral contraceptive versus local treatment versus intense pulsed light combined with vacuum in endocrine acne in women.

Ianosi S, Neagoe D, Branisteanu DE, Popescu M, Calina D, Zlatian O, Docea AO, Marinas MC, Iordache AM, Mitruț P, Ianosi G.

J Biol Regul Homeost Agents. 2018 May-Jun;32(3):711-718.

PMID:
29921404
4.

Comparing HIV risk-related behaviors between 2 RDS national samples of MSM in Brazil, 2009 and 2016.

Guimarães MDC, Kendall C, Magno L, Rocha GM, Knauth DR, Leal AF, Dourado I, Veras MA, Brito AM, Kerr LRFS; Brazilian HIV/MSM Surveillance Group.

Medicine (Baltimore). 2018 May;97(1S Suppl 1):S62-S68. doi: 10.1097/MD.0000000000009079.

5.

Oral contraceptives for pain associated with endometriosis.

Brown J, Crawford TJ, Datta S, Prentice A.

Cochrane Database Syst Rev. 2018 May 22;5:CD001019. doi: 10.1002/14651858.CD001019.pub3. Review.

PMID:
29786828
6.

Barriers to implementation of long-acting reversible contraception: A systematic review.

Phillips J, Sandhu P.

J Am Assoc Nurse Pract. 2018 Apr;30(4):236-243. doi: 10.1097/JXX.0000000000000019. Review.

PMID:
29757790
7.

Low-dose LNG-IUS as Therapy for Endometrial Hyperplasia. A Prospective Cohort Pilot Study.

Sletten ET, Arnes M, Vereide AB, Ørbo A.

Anticancer Res. 2018 May;38(5):2883-2889.

PMID:
29715112
8.

Dietary intake and eating behavior in depot medroxyprogesterone acetate users: a systematic review.

Silva P, Qadir S, Fernandes A, Bahamondes L, Peipert JF.

Braz J Med Biol Res. 2018;51(6):e7575. doi: 10.1590/1414-431x20187575. Epub 2018 Apr 23. Review.

9.

Levonorgestrel-releasing intra-uterine systems as female contraceptives.

Grandi G, Farulla A, Sileo FG, Facchinetti F.

Expert Opin Pharmacother. 2018 May;19(7):677-686. doi: 10.1080/14656566.2018.1462337. Epub 2018 Apr 11. Review.

PMID:
29637798
10.

Highlights From the U.S. Selected Practice Recommendations for Contraceptive Use.

Holland AC, Strachan AT, Pair L, Stallworth K, Hodges A.

Nurs Womens Health. 2018 Apr;22(2):181-190. doi: 10.1016/j.nwh.2018.02.006.

PMID:
29628057
11.

Demand for Women's Health Services in Northern Nigeria: A Review of the Literature.

Sinai I, Anyanti J, Khan M, Daroda R, Oguntunde O.

Afr J Reprod Health. 2017 Jun;21(2):96-108. Review.

PMID:
29624944
12.

Nanotechnology and the future of condoms in the prevention of sexually transmitted infections.

Yah CS, Simate GS, Hlangothi P, Somai BM.

Ann Afr Med. 2018 Apr-Jun;17(2):49-57. doi: 10.4103/aam.aam_32_17. Review.

13.

Effect of self-administration versus provider-administered injection of subcutaneous depot medroxyprogesterone acetate on continuation rates in Malawi: a randomised controlled trial.

Burke HM, Chen M, Buluzi M, Fuchs R, Wevill S, Venkatasubramanian L, Dal Santo L, Ngwira B.

Lancet Glob Health. 2018 May;6(5):e568-e578. doi: 10.1016/S2214-109X(18)30061-5. Epub 2018 Mar 8.

14.

Evaluation and Treatment of Hirsutism in Premenopausal Women.

Mimoto MS, Oyler JL, Davis AM.

JAMA. 2018 Apr 17;319(15):1613-1614. doi: 10.1001/jama.2018.2611. No abstract available.

15.

Weighing the Risks and Benefits of Hormonal Contraception.

Peachman RR.

JAMA. 2018 Mar 20;319(11):1083-1084. doi: 10.1001/jama.2018.0448. No abstract available.

PMID:
29490363
16.

Targeting strategies of mHealth interventions for maternal health in low and middle-income countries: a systematic review protocol.

Ilozumba O, Abejirinde IO, Dieleman M, Bardají A, Broerse JEW, Van Belle S.

BMJ Open. 2018 Feb 24;8(2):e019345. doi: 10.1136/bmjopen-2017-019345. Review.

17.

Hormonal Contraceptives Increase Breast Cancer Risk.

Rosenberg K.

Am J Nurs. 2018 Mar;118(3):69. doi: 10.1097/01.NAJ.0000530943.19361.8b.

PMID:
29470222
18.

A randomized controlled trial of an intervention delivered by mobile phone app instant messaging to increase the acceptability of effective contraception among young people in Tajikistan.

McCarthy O, Ahamed I, Kulaeva F, Tokhirov R, Saibov S, Vandewiele M, Standaert S, Leurent B, Edwards P, Palmer M, Free C.

Reprod Health. 2018 Feb 13;15(1):28. doi: 10.1186/s12978-018-0473-z. Erratum in: Reprod Health. 2018 Mar 26;15(1):52.

19.

Trial protocol: a parallel group, individually randomized clinical trial to evaluate the effect of a mobile phone application to improve sexual health among youth in Stockholm County.

Nielsen A, De Costa A, Bågenholm A, Danielsson KG, Marrone G, Boman J, Salazar M, Diwan V.

BMC Public Health. 2018 Feb 5;18(1):216. doi: 10.1186/s12889-018-5110-9.

20.

A systematic review and meta-analysis of venous thrombosis risk among users of combined oral contraception.

Dragoman MV, Tepper NK, Fu R, Curtis KM, Chou R, Gaffield ME.

Int J Gynaecol Obstet. 2018 Jun;141(3):287-294. doi: 10.1002/ijgo.12455. Epub 2018 Feb 22. Review.

Supplemental Content

Loading ...
Support Center